Pediatrics

Search results

• Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease

  Bana Jabri-Bendelac

  1/11/22 → 2/11/22

  12 items of Media coverage

  Press/Media

• Plexision Aims to Deliver Single-Day Results for Organ Transplant Rejection Testing With Antigen Test

  John Bucuvalas

  28/10/22

  1 item of Media coverage

  Press/Media

• Nuvance Patient Empowerment Workshops Continuing

  David Ezon

  21/10/22

  1 item of Media coverage

  Press/Media

• Mount Sinai's Yvette Calderon, MD, MS, Elected To National Academy Of Medicine For Contributions To Emergency Medicine

  Eric Nestler, Yvette Calderon, Ramon Parsons, Brendan Carr, Joseph Buxbaum, Kenneth L. Davis, Valentin Fuster & Bruce Gelb

  20/10/22

  1 item of Media coverage

  Press/Media

• Mount Sinai's Yvette Calderon, MD, MS, Elected to National Academy of Medicine for Contributions to Emergency Medicine

  Kenneth L. Davis, Eric J. Nestler, Valentin Fuster, Yvette Calderon, Ramon Parsons, Brendan Carr, Albert Siu, Joseph Buxbaum & Bruce Gelb

  19/10/22

  1 item of Media coverage

  Press/Media

• Mount Sinai’s Yvette Calderon, MD, MS, Elected to National Academy of Medicine for Contributions to Emergency Medicine

  Eric Nestler, Yvette Calderon, Ramon Parsons, Brendan Carr, Albert Siu, Joseph Buxbaum, Kenneth L. Davis, Valentin Fuster & Bruce Gelb

  19/10/22

  3 items of Media coverage

  Press/Media

• Chutes & Ladders—BIO CEO resigns amid reports of dissent within organization

  Harold Bernstein

  14/10/22

  1 item of Media coverage

  Press/Media

• Harold Bernstein exits BioMarin and enters Maze

  Harold Bernstein

  14/10/22

  1 item of Media coverage

  Press/Media

• Movers & Shakers: CEO Shakeups at BIO, Passage Bio and Palisade Bio

  Harold Bernstein

  14/10/22

  1 item of Media coverage

  Press/Media

• Maze Therapeutics Appoints Harold Bernstein, M.D., Ph.D., as President, Research and Development and Chief Medical Officer

  Harold Bernstein

  12/10/22 → 13/10/22

  6 items of Media coverage

  Press/Media

• Maze Therapeutics Appoints Harold Bernstein, M.D., Ph.D., as President, Research and Development and Chief Medical Officer

  Harold Bernstein

  12/10/22

  1 item of Media coverage

  Press/Media

• NYU Langone Health: Experimental Treatment Approach Counters Allergic Asthma Without Weakening Flu Defenses

  Maria Curotto de Lafaille

  8/10/22

  1 item of Media coverage

  Press/Media

• Experimental Treatment Approach Counters Allergic Asthma without Weakening Flu Defenses

  Maria Curotto de Lafaille

  7/10/22 → 8/10/22

  109 items of Media coverage

  Press/Media

• NYU: Experimental Treatment Approach Counters Allergic Asthma Without Weakening Flu Defenses

  Maria Curotto de Lafaille

  7/10/22

  1 item of Media coverage

  Press/Media

• Marla Dubinsky, MD: The Future of IL-23 Treatments for IBD

  Marla Dubinsky

  30/09/22

  2 items of Media coverage

  Press/Media

• Mentoring Aspiring Biomedical Scientists

  Brian Sweis, Hala Harony-Nicolas, Jessica Ables, Emily Bernstein & Maria Curotto de Lafaille

  29/09/22

  1 item of Media coverage

  Press/Media

• APPROVAL OF NEW PEDIATRIC PHYSICIAN RESIDENCY PROGRAM HELPS IMPROVE CARE FOR CHILDREN AND FAMILIES IN NEVADA

  Caroline Barangan

  23/09/22

  1 item of Media coverage

  Press/Media

• Glimmer of Hope for Boy With Rare Disorder

  Alexander Kolevzon

  22/09/22

  1 item of Media coverage

  Press/Media

• Approval of New Pediatric Physician Residency Program Helps Improve Care for Children and Families in Nevada

  Caroline Barangan

  22/09/22

  100 items of Media coverage

  Press/Media

• Risankizumab Could Usher in Targeted Medicine for Inflammatory Diseases

  Marla Dubinsky

  21/09/22 → 22/09/22

  2 items of Media coverage

  Press/Media

• Prometheus Laboratories Partners with Takeda on Crohn’s Disease Prognostic Tool

  Marla Dubinsky

  16/09/22

  1 item of Media coverage

  Press/Media

• Prometheus Laboratories Announces Partnership With Takeda To Launch CDPATH™, A Personalized Prognostic Tool Advancing Innovation For Crohn's Disease Patients

  Marla Dubinsky

  16/09/22

  1 item of Media coverage

  Press/Media

• What experts say about safe preparation of infant formula

  Melissa Glassman

  14/09/22

  1 item of Media coverage

  Press/Media

• Prometheus Laboratories Announces Partnership With Takeda To Launch CDPATH, A Personalized Prognostic Tool Advancing Innovation For Crohn's Disease Patients'

  Marla Dubinsky

  14/09/22

  60 items of Media coverage

  Press/Media

• Prometheus Laboratories Announces Partnership With Takeda To Launch CDPATH, A Personalized Prognostic Tool Advancing Innovation For Crohn's Disease Patients'

  Marla Dubinsky

  14/09/22

  1 item of Media coverage

  Press/Media